Strategic partnerships Perthera has existing collaborations with academic institutions like Thomas Jefferson University and has a GI Precision Oncology Clinical Studies program (GIPOCS). This indicates strong collaboration potential with healthcare centers and research organizations for co-developed solutions or pilots.

Clinical impact The Perthera Report is clinically proven to improve survival by 2.4x and is trusted by over 1,500 oncologists across 600+ cancer centers, suggesting a compelling value proposition for expanding adoption in mid-to-large oncology networks and hospital systems.

Pancreatic focus Recent emphasis on Perthera Report Pancreatic as a frontline chemotherapy predictor offers a targeted entry point for sales conversations with pancreatic cancer programs, pharma partners focusing on pancreatic therapies, and centers building precision oncology stacks in GI cancer care.

Technology ecosystem The tech stack leverages cloud, data, and engagement tools (AWS, HubSpot, Piwik, WordPress, WooCommerce, Shopify, Vimeo, Google Workspace), enabling scalable deployment, marketing automation, and data integration opportunities to upsell platforms, analytics services, or patient/physician engagement modules.

Growth signals Leadership changes in 2024 (CEO, CMO) combined with ongoing funding and revenue momentum position Perthera for accelerated market expansion; this creates openings for executive-level engagements, co-marketing, and strategic partnerships to scale adoption across oncology networks.